DE69625516T2 - Verwendung von il-10 zur wundheilung mit verminderter narbenbildung - Google Patents

Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Info

Publication number
DE69625516T2
DE69625516T2 DE69625516T DE69625516T DE69625516T2 DE 69625516 T2 DE69625516 T2 DE 69625516T2 DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T2 DE69625516 T2 DE 69625516T2
Authority
DE
Germany
Prior art keywords
decreased scarring
wounds healing
wounds
healing
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625516T
Other languages
English (en)
Other versions
DE69625516D1 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE69625516D1 publication Critical patent/DE69625516D1/de
Publication of DE69625516T2 publication Critical patent/DE69625516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
DE69625516T 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung Expired - Lifetime DE69625516T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (2)

Publication Number Publication Date
DE69625516D1 DE69625516D1 (de) 2003-01-30
DE69625516T2 true DE69625516T2 (de) 2003-09-25

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625516T Expired - Lifetime DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Country Status (13)

Country Link
US (2) US6387364B1 (de)
EP (1) EP0871473B1 (de)
JP (1) JP4050317B2 (de)
AT (1) ATE229814T1 (de)
AU (1) AU719089B2 (de)
CA (1) CA2229078C (de)
DE (1) DE69625516T2 (de)
DK (1) DK0871473T3 (de)
ES (1) ES2187665T3 (de)
GB (1) GB2304047A (de)
PT (1) PT871473E (de)
WO (1) WO1997005894A1 (de)
ZA (1) ZA966744B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941108B1 (de) * 1996-12-04 2002-10-16 Renovo Limited Wundheilung und behandlung von fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
JP2003508496A (ja) * 1999-09-08 2003-03-04 シェーリング コーポレイション 哺乳動物ｃｃｒ６レセプターおよび関連試薬の新規使用
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
AU2002365261A1 (en) * 2001-10-18 2003-09-02 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
NZ545318A (en) * 2003-07-15 2009-06-26 Univ Bar Ilan Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor
ZA200601089B (en) 2003-08-07 2007-05-30 Hearlor Ltd Pharmaceutical compositions and methods for accelerating wound healing
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
JP5105554B2 (ja) * 2006-09-28 2012-12-26 メルク・シャープ・アンド・ドーム・コーポレーション 癌を処置するためのペグ化ｉｌ−１０の使用
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
RU2502520C2 (ru) * 2007-07-30 2013-12-27 Хилор Лтд. Фармацевтическая композиция и относящиеся способы
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
US9035037B2 (en) 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices
EP2238250B1 (de) * 2007-12-21 2017-07-19 CoDa Therapeutics, Inc. Verwendung von anti-connexin 43-polynukleotiden, -peptiden oder antikörpern zur behandlung orthopädischer leiden
WO2009085277A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
WO2009120799A2 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
EP2379115B1 (de) 2008-12-17 2017-10-25 Merck Sharp & Dohme Corp. Herstellung von mono- und di-peg il-10 und verwendungszwecke
NZ594067A (en) * 2009-02-24 2013-03-28 Healor Ltd VISFATIN THERAPEUTIC AGENTS (PEPTIDES, siRNA, FK-866, APO866 ) FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20140112898A1 (en) * 2011-03-31 2014-04-24 President And Fellows Of Harvard College Unique population of regulatory t cells that regulate tissue regeneration and wound healing
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
BR112015026122A8 (pt) 2013-04-18 2020-01-21 Armo Biosciences Inc agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (de) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
CA2069090A1 (en) * 1989-11-21 1991-05-22 John A. Hamilton Anti-inflammatory compositions and methods
DE69130289T2 (de) 1990-04-11 1999-06-02 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
CA2099263C (en) * 1991-01-10 1997-03-11 Martin A. Schwarz Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
SK150596A3 (en) 1993-07-26 1997-04-09 Schering Corp Agonists and antagonists of human interleukin-10
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
EP1621206A1 (de) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimäre Zytokine und ihre Verwendung
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
ES2187665T3 (es) 2003-06-16
ATE229814T1 (de) 2003-01-15
US20020128447A1 (en) 2002-09-12
WO1997005894A1 (en) 1997-02-20
US6387364B1 (en) 2002-05-14
AU719089B2 (en) 2000-05-04
ZA966744B (en) 1998-02-09
CA2229078C (en) 2010-04-20
PT871473E (pt) 2003-03-31
EP0871473B1 (de) 2002-12-18
EP0871473A1 (de) 1998-10-21
US7052684B2 (en) 2006-05-30
GB2304047A (en) 1997-03-12
JPH11510505A (ja) 1999-09-14
JP4050317B2 (ja) 2008-02-20
GB9516287D0 (en) 1995-10-11
AU6666096A (en) 1997-03-05
CA2229078A1 (en) 1997-02-20
DE69625516D1 (de) 2003-01-30
DK0871473T3 (da) 2003-04-14

Similar Documents

Publication Publication Date Title
DE69625516T2 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
ATE395022T1 (de) Zusammensetzung und verfahren zur beschleunigung von wunden- und brandheilung
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
ATE298579T1 (de) Phosphnatanaloge von mannose-6-phosphate und deren verwendung zur förderung der heilung von wunden oder fibrotischen störungen mit verminderter narbenbildung
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE68905342T2 (de) Verwendung von minoxidil zur wundheilung.
ATE227995T1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung
DE69418931T2 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
ATE320284T1 (de) Verwendung von mindestens einem derivat der 10- hydroxy-2-decenoicsäure in einer zusammensetzung zur förderung der abschuppung der haut
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE69326349T2 (de) Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
DE69712287D1 (de) Verwendung von Sulbutiamin zur Behandlung von psychomotorischen oder psychointellektuellen Beschwerden
DE59712374D1 (de) Verwendung von hcc-1 zur behandlung von thrombozytopenien
DE69912778D1 (de) Verwendung von wundverbänden zur behandlung von akuten wunden
FI933236A0 (fi) Foerfarande foer frekvensval i soekanordning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition